Adeno-associated virus type 5 infection via PDGFRα is associated with Interstitial lung disease in systemic sclerosis and generates composite peptides and epitopes recognized by the agonistic immunoglobulins present in patients with systemic sclerosis

By sjmartinez • November 18, 2023

Moroncini G, Svegliati S, Grieco A, Cuccioloni M, Mozzicafreddo M, Paolini C, Agarbati S, Spadoni T, Amoresano A, Pinto G, Chen Q, Benfaremo D, Tonnini C, Senzacqua M, Alizzi S, Nieto K, Finke D, Viola N, Amico D, Galgani M, Gasparini S, Zuccatosta L, Menzo S, Müller M, Kleinschmidt J, Funaro A, Giordano A, La Cava A, Dorfmuller P, Amoroso A, Pucci P, Pezone A, Avvedimento EV, Gabrielli A. Adeno-associated virus type 5 infection via PDGFRα is associated with Interstitial lung disease in systemic sclerosis and generates composite peptides and epitopes recognized by the agonistic immunoglobulins present in patients with systemic sclerosis. Arthritis Rheumatol. 2023 Nov 16. doi: 10.1002/art.42746. Epub ahead of print. PMID: 37975161.

Tags: Publications, Rheumatology

Host targets of candidalysin

Lin J, Filler SG. Host targets of candidalysin. PLoS Pathog. 2025 Jun 23;21(6):e1013284. doi: 10.1371/journal.ppat.1013284. PMID: 40549807; PMCID: PMC12184922.

Chimneys

Reuben DB. Chimneys. JAMA Intern Med. 2025 Jun 23. doi: 10.1001/jamainternmed.2025.1822. Epub ahead of print. PMID: 40549397.

Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer

LeVee A, Peluso E, Lechner MG, Ruel N, Mortimer J, Kang I, Tsai K. Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in[...]